Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other financing activities (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Other financing activities for 13 consecutive years, with $118000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 31.11% to $118000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $213000.0 through Dec 2025, down 90.52% year-over-year, with the annual reading at $213000.0 for FY2025, 90.52% down from the prior year.
  • Other financing activities hit $118000.0 in Q4 2025 for Ironwood Pharmaceuticals, up from $1000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $17.5 million in Q4 2021 to a low of -$8.0 million in Q3 2024.
  • Historically, Other financing activities has averaged $2.5 million across 5 years, with a median of $1.4 million in 2022.
  • Biggest five-year swings in Other financing activities: soared 887.76% in 2021 and later crashed 61838.46% in 2024.
  • Year by year, Other financing activities stood at $17.5 million in 2021, then crashed by 70.44% to $5.2 million in 2022, then tumbled by 66.85% to $1.7 million in 2023, then tumbled by 94.74% to $90000.0 in 2024, then skyrocketed by 31.11% to $118000.0 in 2025.
  • Business Quant data shows Other financing activities for IRWD at $118000.0 in Q4 2025, $1000.0 in Q3 2025, and $88000.0 in Q2 2025.